Drug-tolerant persister (DTP) cell populations were originally discovered in antibiotic-
resistant bacterial biofilms. Similar populations with comparable features have since been …

Epigenetic dysregulation is increasingly appreciated as a hallmark of cancer, including
disease initiation, maintenance and therapy resistance. As a result, there have been …

Advancements in precision oncology over the past decades have led to new therapeutic
interventions, but the efficacy of such treatments is generally limited by an adaptive process …

Complex gene regulatory mechanisms underlie differentiation and reprogramming.
Contemporary single-cell lineage-tracing (scLT) methods use expressed, heritable DNA …

The emergence of drug resistance is the most substantial challenge to the effectiveness of
anticancer therapies. Orthogonal approaches have revealed that a subset of cells, known as …

Metastatic melanoma is among the most enigmatic advanced cancers to clinically manage
despite immense progress in the way of available therapeutic options and historic …

Disease relapse driven by acquired drug resistance limits the effectiveness of most systemic
anti-cancer agents. Targeting persistent cancer cells in residual disease before relapse has …

Single-cell sequencing has characterized cell state heterogeneity across diverse healthy
and malignant tissues. However, the plasticity or heritability of these cell states remains …

Non-genetic mechanisms have recently emerged as important drivers of anticancer drug
resistance. Among these, the drug tolerant persister (DTP) cell phenotype is attracting more …

In the past decade, remarkable progress in cancer medicine has been achieved by the
development of treatments that target DNA sequence variants. However, a purely genetic …